Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Champions Oncology (CSBR) Cost of Revenue (2016 - 2025)

Historic Cost of Revenue for Champions Oncology (CSBR) over the last 16 years, with Q4 2025 value amounting to $7.3 million.

  • Champions Oncology's Cost of Revenue fell 223.48% to $7.3 million in Q4 2025 from the same period last year, while for Oct 2025 it was $29.1 million, marking a year-over-year decrease of 153.38%. This contributed to the annual value of $28.4 million for FY2025, which is 344.21% down from last year.
  • Latest data reveals that Champions Oncology reported Cost of Revenue of $7.3 million as of Q4 2025, which was down 223.48% from $8.0 million recorded in Q3 2025.
  • In the past 5 years, Champions Oncology's Cost of Revenue ranged from a high of $8.0 million in Q3 2025 and a low of $4.6 million during Q1 2021
  • In the last 5 years, Champions Oncology's Cost of Revenue had a median value of $7.2 million in 2024 and averaged $6.8 million.
  • As far as peak fluctuations go, Champions Oncology's Cost of Revenue surged by 3856.8% in 2022, and later plummeted by 1569.63% in 2025.
  • Over the past 5 years, Champions Oncology's Cost of Revenue (Quarter) stood at $5.6 million in 2021, then surged by 32.7% to $7.4 million in 2022, then fell by 11.08% to $6.6 million in 2023, then grew by 12.24% to $7.4 million in 2024, then dropped by 2.23% to $7.3 million in 2025.
  • Its Cost of Revenue stands at $7.3 million for Q4 2025, versus $8.0 million for Q3 2025 and $7.3 million for Q2 2025.